Radiopharm TheranosticsRADX
13F holders, Q2 2025 (June 30)5holders +2
2new positions
0sold out
$4.64avg. 13F price*
At the end of Q2 2025, 5 institutions reported holding Radiopharm Theranostics Ltd. (RADX) in their 13F filings, up 2 from Q1 2025. 2 opened new positions and 0 sold out. The largest holders were Silverarc Capital Management, LLC ($870K), Regal Partners Ltd ($422K) and Affinity Asset Advisors, LLC ($166K).
- Company
- Radiopharm Theranostics Ltd.
- CUSIP
- 75041J101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $119K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 25,740 shares bought and 28,965 shares sold, net −3,225 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Silverarc Capital Management, LLC | 0.18% | No change | 187,406 | $870K |
| Regal Partners Ltd | 0.04% | No change | 90,909 | $422K |
| Affinity Asset Advisors, LLC | 0.03% | Reduce -44.8% | 35,635 | $166K |
| UBS Group AG | 0.00% | New | 17,740 | $82K |
| PNC Financial Services Group, Inc. | 0.00% | New | 8,000 | $37K |
"% of holder's portfolio" is RADX's weight in each manager's 13F, not the share of Radiopharm Theranostics Ltd. the manager owns.